Platinum-based chemotherapy is the cornerstone of treatment of advanced non-small-cell lung cancer ( NSCLC ) patients , but the efficacy of adding cisplatin to single-agent chemotherapy remains to be demonstrated in prospective phase III trials dedicated to elderly patients .